These characteristics make of MitoQ a potential first-in-class drug to prevent cancer metastasis, which we tested here in vitro using highly metastatic human triple-negative breast cancer (TNBC) and HER2+ breast cancer cell lines. This evidence concerns the gene ERBB2 and breast cancer.